Navigation Links
PTC Therapeutics to Present at Credit Suisse Annual Health Care Conference
Date:11/5/2013

SOUTH PLAINFIELD, N.J., Nov. 5, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 2013 Credit Suisse Annual Health Care Conference on Tuesday, November 12 at 4:30 pm ET.

(Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO )

The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com. The presentation will be archived for two weeks following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

About PTC Therapeutics, Inc.

PTC is biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and form the basis for collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website www.ptcbio.com

Forward Looking Statements:

Any statements in this press release about future expectations, plans and prospects for PTC, the development of and potential market for our product candidates,  and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, the availability or commercial potential of our product candidates and other factors discussed in the "Risk Factors" in the most recent Quarterly Report, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views only as of the date of this release. We anticipate that subsequent events and developments will cause the our views to change. However, while PTC may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing PTC's views as of any date subsequent to the date of this press release.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alba Therapeutics Appoints Wendy Perrow Chief Executive Officer
2. Sorrento Therapeutics Enters into Antibody and Vaccine Development Alliance for the Prevention and Treatment of Obesity
3. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
4. Mast Therapeutics Reports Third Quarter 2013 Financial Results
5. Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
6. Echo Therapeutics Schedules Third Quarter 2013 Financial Results for Thursday, November 7, 2013
7. G1 Therapeutics to Present at Southeast BIO Investor & Partnering Forum
8. Cell Therapeutics Reports Third Quarter 2013 Financial Results
9. Sorrento Therapeutics Announces Closing of Public Offering of Common Stock
10. Abide Therapeutics Appoints Dr. Gary ONeill as Vice President of Biology
11. Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... 20, 2017  Prime Therapeutics LLC (Prime) released this statement ... following today,s Institute for Clinical and Economic Review,s (ICER) ... effectiveness and value of abuse-deterrent formulations (ADF) of opioids. Prime ... at the meeting. ... benefit to the use of abuse-deterrent formulations (ADF) in opioids ...
(Date:7/17/2017)... 17, 2017  MedX Holdings, Inc., the manufacturer and ... and rehabilitation equipment, today announced the national roll out ... considered the gold standard for the treatment of low ... strengthening equipment. How ... physician or practice who prescribe the MedX Home Back ...
(Date:7/14/2017)... International plc (NASDAQ: ENDP ) will announce its second-quarter ... senior management team will host a conference call and webcast before ... The dial-in number to access the call is U.S./ ... is 45397076. Please dial in 10 minutes prior to the scheduled ... of the call will be available from August 8, 2017 at ...
Breaking Medicine Technology:
(Date:7/26/2017)... Baton Rouge, Louisiana (PRWEB) , ... July 26, 2017 , ... ... their doctors to offer the ability for patients to schedule an appointment online in ... LocalMed directly from the Six Month Smiles provider directory will bring more Six Month ...
(Date:7/26/2017)... ... ... M. Musielak, a partner at the Andrew Cores Family Law Group, a division ... earlier this year. She will serve the membership in this capacity for a term of ... the organization’s by-laws. , Musielak joined the Andrew Cores Family Law Group ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... department joining as Regional Account Manager for the Northeast and Florida regions. In ... liquidation of their obsolete medical assets. , Jennifer joins Centurion with a wealth ...
(Date:7/25/2017)... ... July 25, 2017 , ... Nautilus Hyosung America ... today announced its partnership with financial technology company, Automated Transaction Delivery (ATD), to ... solution lies within Hyosung’s superior ATMs, assisted self-service devices and associated software. ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Engineers at ... bio-compatible, because it produces the same kind of electrical energy that the body uses. ... form of moving electrons. This flow of electrons out of the battery is generated ...
Breaking Medicine News(10 mins):